Contents Link Navigation Link
PARTNERSHIP

Targeting, Attacking, and Eradicating Cancers®

Pexa-Vec Partnerships

Targeting, Attacking, and Eradicating Cancers®

PEXA-VEC Partnership

Partnered

Unpartnered (SillaJen territory)

  • KOREA
    greencross
    Liver Cancer (HCC)
    KR Develelopment & Commercialization rights
  • CHINA
    pharm
    Liver Cancer (HCC)
    CN Develelopment & Commercialization rights
  • EUROPE
    transgene
    Liver Cancer (HCC) & CRC
    EU Develelopment & Commercialization rights (40 countries)
  • UNITED STATES
    regeneron
    Kidney Cancer (RCC)
    Clinical Collaboration without rights transaction
    Combination with REGN2810 (PD-1 Blockade)

SillaJen is actively seeking development partners and/or licensing opportunities for all of its assets. For inquiries, please send an email to BD@sillajen.com